-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 8, CDE's official website showed that Hansoh Pharmaceutical's class 1 new drug HS-10380 tablets obtained an implied license for clinical trials and is intended to be used for the treatment of schizophrenia
.
According to data from Minet.
com, in 2020, the total sales of terminal antipsychotic drugs in Chinese public medical institutions and Chinese urban brick-and-mortar pharmacies will exceed 9 billion yuan
.
Class 1 new drug HS-10380 tablets is intended for the treatment of schizophrenia
.
Schizophrenia is a relatively serious mental disorder and one of the most common mental illnesses.
It has become one of the major public health challenges facing China
.
According to data from Minet.
com, in 2020, the total sales of terminal antipsychotic drugs in Chinese urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 9 billion yuan
.
As a major manufacturer in the antipsychotic drug market, Hansoh Pharmaceutical occupies more than 10% of the market share
.
Since the beginning of this year, Hansoh Pharmaceutical has obtained 3 Class 1 new drugs for clinical approval, including HS-10380 tablets, HS-10370 tablets, and HS-10382 tablets
.
At a time when innovative oncology drugs are popular, HS-10380 tablets are a rare psychiatric innovative drug in the innovative R&D pipeline of local pharmaceutical companies
.
.
According to data from Minet.
com, in 2020, the total sales of terminal antipsychotic drugs in Chinese public medical institutions and Chinese urban brick-and-mortar pharmacies will exceed 9 billion yuan
.
Class 1 new drug HS-10380 tablets is intended for the treatment of schizophrenia
.
Schizophrenia is a relatively serious mental disorder and one of the most common mental illnesses.
It has become one of the major public health challenges facing China
.
According to data from Minet.
com, in 2020, the total sales of terminal antipsychotic drugs in Chinese urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 9 billion yuan
.
As a major manufacturer in the antipsychotic drug market, Hansoh Pharmaceutical occupies more than 10% of the market share
.
Since the beginning of this year, Hansoh Pharmaceutical has obtained 3 Class 1 new drugs for clinical approval, including HS-10380 tablets, HS-10370 tablets, and HS-10382 tablets
.
At a time when innovative oncology drugs are popular, HS-10380 tablets are a rare psychiatric innovative drug in the innovative R&D pipeline of local pharmaceutical companies
.
